Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT

Fineline Cube Dec 22, 2025
Company Drug

GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD

Fineline Cube Dec 22, 2025
Company Drug

NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review

Fineline Cube Aug 10, 2022

The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...

Company Drug

Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne

Fineline Cube Aug 10, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...

Company Policy / Regulatory

NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme

Fineline Cube Aug 10, 2022

The National Healthcare Security Administration (NHSA) has announced the results of a special investigation, revealing...

Company

FibroGen’s Roxadustat Sales in China Rise Despite Price Cut

Fineline Cube Aug 10, 2022

US firm FibroGen Inc. (NASDAQ: FGEN), which operates subsidiaries in Beijing and Shanghai, released its...

Company Drug

Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study

Fineline Cube Aug 10, 2022

China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...

Company

Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut

Fineline Cube Aug 10, 2022

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...

Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study

Fineline Cube Aug 10, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...

Company Drug

Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial

Fineline Cube Aug 10, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...

Company Drug

Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study

Fineline Cube Aug 9, 2022

Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...

Company Deals

Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China

Fineline Cube Aug 9, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment

Fineline Cube Aug 9, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...

Medical Device

GeneoDx Biotech’s Cervical Cancer Screening Kit Wins NMPA Approval

Fineline Cube Aug 9, 2022

Shanghai GeneoDx Biotech Co., Ltd, a medical diagnosis unit of Sinopharm, has announced that it...

Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty and Angelguide Approved in Colombia

Fineline Cube Aug 9, 2022

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced...

Company Drug

HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy

Fineline Cube Aug 9, 2022

China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...

Company Deals

Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion

Fineline Cube Aug 9, 2022

Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...

Policy / Regulatory R&D

CDE Issues Q&As on COVID-19 Antiviral Drug Evaluation Criteria

Fineline Cube Aug 9, 2022

The Center for Drug Evaluation (CDE) has published a list of Q&As regarding the non-clinical...

Company Medical Device

NMPA Approves BioFire Diagnostics’ Encephalitis/Meningitis Detection Kit

Fineline Cube Aug 9, 2022

The National Medical Products Administration (NMPA) website indicates that BioFire Diagnostics LLC’s encephalitis/meningitis multiple pathogen...

Company Deals R&D

BioDuro-Sundia and X-Chem Form Long-Term Partnership for Drug Discovery

Fineline Cube Aug 8, 2022

Two China-based companies, the Contract Research, Development, and Manufacturing Organization (CRDMO) BioDuro-Sundia and X-Chem, have...

Company Drug

Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion

Fineline Cube Aug 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...

Company Deals Digital

Hywin Holdings to Acquire Life Infinity for Health Management Expansion

Fineline Cube Aug 8, 2022

China-based wealth management firm Hywin Holdings is set to move into the health management business...

Posts pagination

1 … 573 574 575 … 600

Recent updates

  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
  • GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD
  • EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
  • SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Company Drug

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT

Company Drug

GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD

Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.